Global multi-stakeholder endorsement of the MAFLD definition.
(2022) The lancet. Gastroenterology & hepatology — Vol. 7, n° 5, p. 388-390 (2022)
Files
LancetGH2022March3Letter.pdf
Open Access - Adobe PDF
- 46.99 KB
Details
- Authors
- et. al.
- Abstract
- (en) Comprising over 1000 signatories representative of multiple stakeholders, including hepatologists, internists, diabetologists, endocrinologists, paediatricians, primary-care providers, nephrologists, cardiologists, pathologists, patient advocates, nurses, nutritionists, and pharmaceutical experts from over 134 countries, we—the undersigned—endorse both the name metabolic (dysfunction)-associated fatty liver disease (MAFLD) as an overarching term and its definition for fatty liver diseases associated with metabolic dysregulation. We advocate for this change because it more accurately reflects the underlying pathogenesis of the disease than does the previously used term, non-alcoholic fatty liver disease (NAFLD). Furthermore, we believe that this designation will enhance our ability to advance the science of fatty liver disease and to improve patient care. 4 , 5 This open letter represents the voices of individuals and multiple stakeholders across the global liver health community; it is not intended to devalue any other initiative, but to complement and inform them.
- Affiliations
Citations
Méndez-Sánchez, N., Bugianesi, E., Gish, R. G., Lammert, F., Tilg, H., Nguyen, M. H., Sarin, S. K., Fabrellas, N., Zelber-Sagi, S., Fan, J.-G., Shiha, G., Targher, G., Zheng, M.-H., Chan, W.-K., Vinker, S., Kawaguchi, T., Castera, L., Yilmaz, Y., Korenjak, M., et al. (2022). Global multi-stakeholder endorsement of the MAFLD definition. The lancet. Gastroenterology & hepatology, 7(5), 388-390. https://doi.org/10.1016/S2468-1253(22)00062-0 (Original work published 2022)